Johnson & Johnson is the eighth largest pharmaceutical company and the world’s largest seller of health care products. While remaining wildly successful, the company has been associated with numerous scandals over the years, including the recall of 31 million bottles of Tylenol in 1982.
Bayer Health Care Pharmaceuticals Inc., a specialty pharmaceutical company, develops, manufactures, and markets pharmaceutical products for diagnosing, preventing, and treating diseases for human health. The company focuses on women’s healthcare, diagnostic imaging, general medicine, hematology/neurology, and oncology products.
Boehringer Ingelheim is a leading global pharmaceutical, German-based company, with about $15.1 billion revenue reported in 2014. They specialize in researching, developing and manufacturing high-quality pharmaceutical and medical products for humans and animals, and are best known for developing several groundbreaking medications, including Pradaxa®.
Patients who took Pradaxa® or XARELTO® allege the drug caused a variety of adverse effects and have filed personal injury and wrongful death claims in federal courts against the drug’s manufacturers, Boehringer Ingelheim, Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals.
XARELTO® and Pradaxa®
XARELTO® and Pradaxa® are both new types of blood thinner prescription medicines. XARELTO® is developed by Johnson & Johnson’s New Jersey-based Janssen Pharmaceuticals and Bayer Health Care, while Pradaxa® is manufactured by a competing company called Boehringer-Ingelheim. The manufacturers promoted these drugs as a superior alternative to warfarin (Coumadin, Jantoven), which had been the go-to anticoagulation therapy for the past 60 years, saying Pradaxa® or XARELTO® have fewer contraindications and require less frequent monitoring than warfarin.
With a drug of this sort there are expected risks and complications because the medication interferes with the blood’s normal ability to form clots. With older anticoagulant medications, internal bleeding complications can be managed by administering a reversal agent or antidote drug which restores the blood’s ability to clot. However, there is no known reversal agent for Pradaxa® or XARELTO®, so hemorrhaging will continue until the drug is flushed out of the system. This poses a serious threat for patients because by the time the drug is cleared from their bodies, they may have suffered irreversible damage or even death.
Patients who took Pradaxa® or XARELTO® allege the drug caused a variety of adverse effects including uncontrollable bleeding, intestinal bleeding, brain hemorrhaging, rectal bleeding, and death. More than 50 of these patients have filed personal injury and wrongful death claims in federal courts against Bayer Healthcare and Johnson & Johnson’s Janssen Pharmaceuticals. The claims are made on the basis of a variety of alleged infractions on the part of the manufacturers, such as the defective drug design, the failure to conduct adequate research to assess the safety of the drug, and the failure to adequately warn consumers of bleeding danger. To learn more about Pradaxa® or XARELTO® lawsuits, visit our Lawsuit Information page.
We Can Help
If you or a family member have experienced a serious bleeding complication after taking Pradaxa® or XARELTO®, call us now at (800) 210-4539 or fill out our online form for a free consultation. Our experienced team of personal injury attorneys will listen to your story, assess your chances for a successful claim, advise you on how to move forward, and help you do the legwork. We can help you obtain a just settlement for your pain and suffering.